PHP
KPRX icon

Parkman Healthcare Partners’s Kiora Pharmaceuticals KPRX Stock Holding History

Parkman Healthcare Partners’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-210
Closed -$275K – 80
2021
Q2 		$275K Buy
210
+1
+0.5% +$1.55K 0.06% 81
2021
Q1 		$375K Buy
+209
New +$456K 0.09% 83

Other funds holding KPRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SCA
Sassicaia Capital Advisers Jericho, New York $88.8M AUM 146.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tuttle Capital Management Riverside, Connecticut $60.8M AUM 17.47% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Parkman Healthcare Partners's KPRX Position: Q3 2021 in Review

Parkman Healthcare Partners sold out of Kiora Pharmaceuticals (KPRX) in Q3 2021, closing a stake of 210 shares — an estimated $275K sold.

Parkman Healthcare Partners first reported a position in KPRX in Q1 2021 and held it in 2 quarters. The position peaked at $375K in Q1 2021. 19 funds tracked by Wall St. Rank hold KPRX as of Q3 2021.

  • Parkman Healthcare Partners reported no remaining Kiora Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Parkman Healthcare Partners sold 210 Kiora Pharmaceuticals shares in Q3 2021, an estimated $275K.
  • Parkman Healthcare Partners first reported a position in Kiora Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Parkman Healthcare Partners's Kiora Pharmaceuticals position peaked at $375K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q3 2021.

Based on Parkman Healthcare Partners's 13F filing for Q3 2021, filed 12 Nov 2021.